Keywords: ALP; Alkaline phosphatase; BFR; bone formation rate; BSP; Bone sialoprotein; BV/TV; bone volume/total volume, trabecular bone fraction; CTX; carboxy-terminal collagen crosslinks; Conn.D; connectivity density; rHuEPO; Erythropoietin (EPO)/recombinant human
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: dialysis; ERI; ESA; hemodiafiltration; rHuEPO;
Keywords: rHuEPO; Athletes; Doping; Antibody; Aptamer;
Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Aβ expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer's disease: A pilot study
Keywords: Chronic kidney disease; Alzheimer's diseases; Cognitive dysfunction; Platelet APP/ Aβ; rHuEPO;
Detection of neutralizing antibodies to erythropoietin by inhibition of rHuEPO-stimulated EGR1 gene expression in the UT-7/EPO cell line
Keywords: EPO; erythropoietin; IFN; interferon; IL-3; interleukin-3; NAb; neutralizing antibodies; PNHS; pooled normal human sera; PRCA; pure red cell aplasia; rHuEPO; recombinant human erythropoietin; Erythropoietin; Neutralizing antibodies; EGR1; Pure red cell ap
Carbamylated darbepoetin derivative prevents endothelial progenitor cell damage with no effect on angiogenesis
Keywords: EPCs; endothelial progenitor cells; EPO; erythropoietin; CKD; chronic kidney disease; rHuEPO; recombinant human erythropoietin; darbe; darbepoetin; C-darbe; carbamylated darbepoetin; TNBSA; trinitrobenzenesulfonic acid; PCNA; proliferating cell nuclear an
Darbepoetin Alfa Administration to Achieve and Maintain Target Hemoglobin Levels for 1 Year in Patients With Chronic Kidney Disease
Keywords: CI; confidence interval; CKD; chronic kidney disease; ESP; erythropoiesis-stimulating protein; GFR; glomerular filtration rate; MDRD; Modification of Diet in Renal Disease; NKF-KDOQI; National Kidney Foundation's Kidney Disease Outcomes Quality Initiative
Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy
Keywords: Elderly cancer patients; Cognitive status (MMSE); Anemia; rHuEPO; Chemotherapy treatment
Current concepts in critical care
Keywords: PAC; pulmonary artery catheter; rHuEpo; recombinant human erythropoietin; SBT; spontaneous breathing trial;
The detection of anti-erythropoietin antibodies in human serum and plasma
Keywords: Anemia; Erythropoietin; Neutralizing anti-erythropoietin antibodies; Cytokines; Radioimmunoprecipitation; Stem cell factor; Thymidine uptake; UT-7/EPO; Bioassay; Ab; antibody; BQL; below quantifiable limits; CRF; chronic renal failure; % CV; percent coeff
FIV-infected cats respond to short-term rHuG-CSF treatment which results in anti-G-CSF neutralizing antibody production that inactivates drug activity
Keywords: BM; bone marrow; CID50; cat median infectious dose; CI; confidence interval; ED50; efficacy dose 50%; FIV; feline immunodeficiency virus; FIP; feline infectious peritonitis; M:E; myeloid:erythroid; rHuEPO; recombinant human erythropoietin; rHuG-CSF; recom
Unit dosing of darbepoetin alfa for thetreatment of anemia in patients with end-stage renal disease being switched from recombinant human erythropoietin: Results of a phase IIIb, 27-week, multicenter, open-label study in Greek patients
Keywords: darbepoetin alfa; dialysis; efficacy; renal disease; rHuEPO; safety; tolerability;